by Novartis Pharmaceuticals UK
with support from Aurora Healthcare Communications, The Clarion Portfolio and Salt
by AstraZeneca
with support from Real Chemistry
by Boehringer Ingelheim and Action for Pulmonary Fibrosis
with support from 11 London (supported by AVT)
by Norgine
with support from earthware
by Novartis UK
with support from Havas Life Medicom
by Novartis Pharmaceuticals UK
with support from Aurora Healthcare Communications, The Clarion Portfolio and Salt
"Heart failure (HF) is a condition that is becoming increasingly prevalent but is poorly recognised. Almost 1 million people in the UK are currently living with HF, with a further 200,000 new patients diagnosed each year.
With a disparity of care across the country, we had to act and create a campaign that would increase the level of understanding of HF in the UK and drive improved diagnosis, care and quality of life for patients.
In-depth research and insights gathering confirmed that there was a significant challenge ahead of us. We needed to create a campaign to drive change in HF, but we knew we could not do this alone.
Collaborating closely with healthcare professionals and patients was key and the only path that could make a difference. With partnership at the heart of the campaign, the strategic direction became clear. By the people, for the people.
The Fighting Failure campaign has created practical resources for the HF community and a spirit to help motivate those living with the disease to seek improvement in their quality of life."
The Fighting Failure entry had great objectives, and good strategy, measurement and learning. The judges liked the “people for the people” aspect and the varied approach to delivery. It had bold ambition across UK stakeholders and focused on the need for information. Exceeded expectations.
Entry deadline | 26 August 2022 |
Extended entry deadline | 2 September 2022* *additional fee applies |
Judging Day | 6 October 2022 |
Company/Team of the Year Interviews | 21 October 2022 |
PMEA Event | 23 November 2022 |